Atlas Venture

Latest fund size

$450M

Announced

December 1, 2024

Global HQ

United States

Members only

Check size

$5M - $25M

Members only

Stage focus

Seed, Series A

Members only

Regions of investment

North America, Europe

Members only

About

Atlas Venture is an early-stage venture capital firm specializing in the creation and investment in biotechnology startups. Headquartered in Cambridge, Massachusetts, Atlas has been instrumental in building breakthrough biotech companies for over 30 years.

Contact info

Website

atlasventure@atlasventure.com

Phone number: USA +1 857 201 2700

‍

Members only

Names, roles, emails and LinkedIn profiles for the team, plus the fund's website.

Investment focus

Atlas Venture employs a seed-led venture creation strategy, partnering with exceptional entrepreneurs and scientists to translate groundbreaking science into life-changing medicines. The firm focuses on building scalable businesses across various disease areas, modalities, and business models, maintaining a disciplined approach to its portfolio.

Members only

What the fund looks for in founders and which sectors it backs.

Fund

In December 2024, Atlas Venture announced the closing of its fourteenth fund, raising $450 million to invest in early-stage biotech startups. This fund continues the firm's commitment to collaborating with talented entrepreneurs to found, seed, incubate, and invest in new biotech companies aimed at bringing novel therapeutics to patients.

Members only

Fund size, LPs and track record.

Other information

Team

The Atlas Venture team comprises experienced professionals dedicated to translating high-impact science into medicines for patients. Key members include:

  • Kevin Bitterman, Ph.D.
  • Bruce Booth, D.Phil.
  • Jean-François Formela, M.D.
  • Michael Gladstone
  • David Grayzel, M.D.
  • Jason Rhodes

‍

Notable Investments and Exits

Atlas Venture has a history of successful investments and exits, including:

  • Nimbus' Tyk2 Program: Acquired by a pharmaceutical partner.
  • Versanis Bio: Acquired by Eli Lilly.
  • Aiolos Bio: Acquired by GSK.
  • Mariana Oncology: Acquired by Novartis.
  • Disc Medicine, Korro Bio, Q32 Bio, and Third Harmonic Bio: Transitioned to public companies.

‍

Members only

Leadership, investment strategy, notable investments and exits.

Unlock this fund's full profile

✓ Emails and LinkedIn for the team

✓ Check size, stage focus and regions of investment

✓ LPs, notable investments and exits

✓ Search and filters across 700+ funds

Unlock this fund and 700+ more

From $14/month, billed yearly. Cancel any time.

Read the newsletter that top VCs and founders keep in their inbox.

Join the weekly newsletter